D.A. Davidson & Co’s Avadel Pharmaceuticals AVDL Stock Holding History

D.A. Davidson & Co’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,000	Closed	-$31K	–	2329
2016 Q4	$31K	Hold	3,000	–	–	﹤0.01%	1774
2016 Q3	$37K	Hold	3,000	–	–	﹤0.01%	1639
2016 Q2	$32K	Hold	3,000	–	–	﹤0.01%	1577
2016 Q1	$33K	Sell	3,000 -18,000	-86%	-$179K	﹤0.01%	1543
2015 Q4	$256K	Hold	21,000	–	–	0.01%	760
2015 Q3	$342K	Hold	21,000	–	–	0.01%	644
2015 Q2	$444K	Hold	21,000	–	–	0.01%	610
2015 Q1	$377K	Sell	21,000 -5,000	-19%	-$78.3K	0.01%	660
2014 Q4	$445K	Hold	26,000	–	–	0.01%	606
2014 Q3	$372K	Sell	26,000 -2,000	-7%	-$28.7K	0.01%	666
2014 Q2	$420K	Buy	28,000 +2,000	+8%	+$24.1K	0.01%	641
2014 Q1	$348K	Sell	26,000 -2,000	-7%	-$21.4K	0.01%	704
2013 Q4	$225K	Buy	+28,000	New	+$198K	0.01%	799

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

D.A. Davidson & Co's AVDL Position: Q1 2017 in Review

D.A. Davidson & Co sold out of Avadel Pharmaceuticals (AVDL) in Q1 2017, closing a stake of 3,000 shares — an estimated $31K sold.

D.A. Davidson & Co first reported a position in AVDL in Q4 2013 and held it in 13 quarters. The position peaked at $445K in Q4 2014. 74 funds tracked by Wall St. Rank hold AVDL as of Q1 2017.

D.A. Davidson & Co reported no remaining Avadel Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
D.A. Davidson & Co sold 3,000 Avadel Pharmaceuticals shares in Q1 2017, an estimated $31K.
D.A. Davidson & Co first reported a position in Avadel Pharmaceuticals in Q4 2013 and held it in 13 quarters.
D.A. Davidson & Co's Avadel Pharmaceuticals position peaked at $445K in Q4 2014.
74 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2017.

Based on D.A. Davidson & Co's 13F filing for Q1 2017, filed 12 May 2017.